Cargando…
Improving thymus implantation for congenital athymia with interleukin‐7
OBJECTIVES: Thymus implantation is a recently FDA‐approved therapy for congenital athymia. Patients receiving thymus implantation develop a functional but incomplete T cell compartment. Our objective was to develop a mouse model to study clinical thymus implantation in congenital athymia and to opti...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665642/ https://www.ncbi.nlm.nih.gov/pubmed/38020730 http://dx.doi.org/10.1002/cti2.1475 |